JP2018525032A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525032A5 JP2018525032A5 JP2018521710A JP2018521710A JP2018525032A5 JP 2018525032 A5 JP2018525032 A5 JP 2018525032A5 JP 2018521710 A JP2018521710 A JP 2018521710A JP 2018521710 A JP2018521710 A JP 2018521710A JP 2018525032 A5 JP2018525032 A5 JP 2018525032A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- pharmaceutical composition
- disease
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010074109 interleukin-22 Proteins 0.000 claims description 21
- 102100030703 Interleukin-22 Human genes 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000028774 intestinal disease Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010017711 Gangrene Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1512486.0A GB201512486D0 (en) | 2015-07-16 | 2015-07-16 | IL22 immunoconjugates |
| GB1512486.0 | 2015-07-16 | ||
| GB1517649.8 | 2015-10-06 | ||
| GBGB1517649.8A GB201517649D0 (en) | 2015-10-06 | 2015-10-06 | IL22 Immunoconjugates |
| GB1521470.3 | 2015-12-04 | ||
| GBGB1521470.3A GB201521470D0 (en) | 2015-12-04 | 2015-12-04 | IL22 immunoconjugates |
| PCT/EP2016/066979 WO2017009469A1 (en) | 2015-07-16 | 2016-07-15 | Il22 immunoconjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525032A JP2018525032A (ja) | 2018-09-06 |
| JP2018525032A5 true JP2018525032A5 (OSRAM) | 2020-02-06 |
| JP6735822B2 JP6735822B2 (ja) | 2020-08-05 |
Family
ID=56413683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521710A Expired - Fee Related JP6735822B2 (ja) | 2015-07-16 | 2016-07-15 | Ｉｌ２２免疫コンジュゲート |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10246502B2 (OSRAM) |
| EP (1) | EP3322719B1 (OSRAM) |
| JP (1) | JP6735822B2 (OSRAM) |
| KR (1) | KR20180030180A (OSRAM) |
| CN (1) | CN108137667A (OSRAM) |
| AU (1) | AU2016293114A1 (OSRAM) |
| BR (1) | BR112018000909A2 (OSRAM) |
| CA (1) | CA2992366A1 (OSRAM) |
| CL (1) | CL2018000131A1 (OSRAM) |
| CO (1) | CO2018000414A2 (OSRAM) |
| CR (1) | CR20180087A (OSRAM) |
| DO (1) | DOP2018000019A (OSRAM) |
| EC (1) | ECSP18010616A (OSRAM) |
| ES (1) | ES2778430T3 (OSRAM) |
| HK (1) | HK1250237A1 (OSRAM) |
| IL (1) | IL256849A (OSRAM) |
| MX (1) | MX2018000687A (OSRAM) |
| PE (1) | PE20180797A1 (OSRAM) |
| PH (1) | PH12018500131A1 (OSRAM) |
| RU (1) | RU2018105687A (OSRAM) |
| WO (1) | WO2017009469A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021514354A (ja) * | 2018-02-21 | 2021-06-10 | ジェネンテック， インコーポレイテッド | ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与 |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| WO2022018126A1 (en) | 2020-07-22 | 2022-01-27 | Philogen S.P.A. | Treatment of pulmonary hypertension |
| TW202221019A (zh) | 2020-07-30 | 2022-06-01 | 美商安維塔生物科學股份有限公司 | 介白素-22融合蛋白及其藥物組合物及治療應用 |
| WO2022073038A1 (en) * | 2020-10-02 | 2022-04-07 | Abbvie Inc. | Interleukin-22 (il-22) fusion proteins and uses thereof |
| CN115703841A (zh) * | 2021-08-10 | 2023-02-17 | 复旦大学 | 白介素17a抗体与白介素22细胞因子融合蛋白及其制备方法与用途 |
| WO2023175077A1 (en) | 2022-03-17 | 2023-09-21 | Philogen S.P.A | Anti-ed-a antibodies for the treatment of pulmonary hypertension |
| WO2025101842A1 (en) * | 2023-11-09 | 2025-05-15 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for targeted delivery of therapeutic agents |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1702069A2 (en) | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| WO2006067633A2 (en) | 2004-12-23 | 2006-06-29 | Molmed Spa | Conjugation product |
| CN101203247A (zh) * | 2005-01-10 | 2008-06-18 | 研究发展基金会 | 用于癌症治疗的靶向嵌合分子 |
| ATE459648T1 (de) | 2005-05-11 | 2010-03-15 | Philogen Spa | Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12 |
| CA2682851C (en) | 2007-04-02 | 2017-01-17 | Philogen S.P.A. | A novel antigen associated with the neovasculature of tumour metastases |
| ES2534726T3 (es) | 2007-07-25 | 2015-04-27 | Philogen S.P.A. | Antígeno ED-A del fibrinógeno que está asociado con linfomas |
| RU2486198C2 (ru) | 2007-10-30 | 2013-06-27 | Филоджен С.П.А. | Антиген, ассоциированный с ревматоидным артритом |
| AU2011205531B2 (en) | 2010-01-13 | 2013-10-10 | Amgen Inc. | IL-22-Fc and hepcidin activity |
| PL2571532T3 (pl) * | 2010-05-14 | 2017-10-31 | Abbvie Inc | Białka wiążące IL-1 |
| CA2903587C (en) * | 2013-03-15 | 2021-09-28 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| AU2014257906A1 (en) * | 2013-04-26 | 2015-12-10 | Philogen S.P.A. | IL4 conjugated to antibodies against extracellular matrix components |
| CN104623639A (zh) * | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | 白介素22二聚体在制备治疗胰腺炎药物中的应用 |
-
2016
- 2016-07-15 MX MX2018000687A patent/MX2018000687A/es unknown
- 2016-07-15 CN CN201680041884.2A patent/CN108137667A/zh active Pending
- 2016-07-15 AU AU2016293114A patent/AU2016293114A1/en not_active Abandoned
- 2016-07-15 WO PCT/EP2016/066979 patent/WO2017009469A1/en not_active Ceased
- 2016-07-15 EP EP16739166.3A patent/EP3322719B1/en active Active
- 2016-07-15 PE PE2018000073A patent/PE20180797A1/es unknown
- 2016-07-15 RU RU2018105687A patent/RU2018105687A/ru not_active Application Discontinuation
- 2016-07-15 KR KR1020187004633A patent/KR20180030180A/ko not_active Withdrawn
- 2016-07-15 HK HK18109660.0A patent/HK1250237A1/zh unknown
- 2016-07-15 BR BR112018000909A patent/BR112018000909A2/pt not_active Application Discontinuation
- 2016-07-15 CR CR20180087A patent/CR20180087A/es unknown
- 2016-07-15 ES ES16739166T patent/ES2778430T3/es active Active
- 2016-07-15 CA CA2992366A patent/CA2992366A1/en not_active Abandoned
- 2016-07-15 JP JP2018521710A patent/JP6735822B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-30 US US15/608,689 patent/US10246502B2/en not_active Expired - Fee Related
-
2018
- 2018-01-11 IL IL256849A patent/IL256849A/en unknown
- 2018-01-15 CL CL2018000131A patent/CL2018000131A1/es unknown
- 2018-01-15 DO DO2018000019A patent/DOP2018000019A/es unknown
- 2018-01-16 PH PH12018500131A patent/PH12018500131A1/en unknown
- 2018-01-17 CO CONC2018/0000414A patent/CO2018000414A2/es unknown
- 2018-02-09 EC ECIEPI201810616A patent/ECSP18010616A/es unknown
-
2019
- 2019-02-20 US US16/280,427 patent/US10858411B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525032A5 (OSRAM) | ||
| US12428497B2 (en) | Multispecific antibody constructs | |
| RU2018105687A (ru) | Иммуноконъюгаты на основе il22 | |
| JP2011509245A5 (OSRAM) | ||
| JP2012501670A5 (OSRAM) | ||
| JP2011207882A5 (OSRAM) | ||
| JP2015533795A5 (OSRAM) | ||
| JP2014511179A5 (OSRAM) | ||
| JP2016524463A5 (OSRAM) | ||
| JP2019205480A5 (OSRAM) | ||
| JP2017534296A5 (OSRAM) | ||
| AU2016208161A1 (en) | IL-17A-binding polypeptides | |
| JP2016520595A5 (OSRAM) | ||
| US10633423B2 (en) | IL-6-binding polypeptide complex | |
| JP2010514413A5 (OSRAM) | ||
| CN108314734A (zh) | 抗pd－1单克隆抗体及其应用 | |
| US12037390B2 (en) | Leptin antibodies and method of reducing leptin | |
| CN118165106A (zh) | 抗犬il-31单克隆抗体及其应用 | |
| JP2025523933A (ja) | 抗アドレノメデュリン非中和抗体、その製造方法及び使用 | |
| JP2019518473A5 (OSRAM) | ||
| CA3164234A1 (en) | Multi-specific antibodies | |
| TW202415677A (zh) | 抗TNFα抗體及組合物 | |
| CN116478278A (zh) | 中性抗体 | |
| PT1495056E (pt) | Métodos de análise | |
| CN117843784A (zh) | 抗人cd73抗体或其抗原结合片段及其应用 |